United Therapeutics (UTHR) Cash & Equivalents Growth (3y) (2012 - 2026)
Powered by 
Analysis
United Therapeutics (UTHR) Cash & Equivalents Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.04 Bn | 624.28 Bn | 17.26 Bn | -1.21% |
| 2 | AbbVie | 440.25 Bn | 433.68 Bn | 12.70 Bn | -9.15% |
| 3 | Merck | 365.65 Bn | 358.51 Bn | 12.21 Bn | 6.56% |
| 4 | Novartis Ag | 266.64 Bn | 258.95 Bn | 11.24 Bn | -11.22% |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn | -28.16% |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | -5.35% |
| 7 | Revolution Medicines | 44.19 Bn | 44.19 Bn | - | - |
| 8 | Incyte | 25.29 Bn | 20.75 Bn | 1.57 Bn | 8.35% |
| 9 | United Therapeutics | 21.44 Bn | 18.77 Bn | 683.80 Mn | 19.10% |
| 10 | Neurocrine Biosciences | 15.52 Bn | 15.13 Bn | 935.80 Mn | 27.55% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 19.10% |
| Mar 31, 2026 | 3.22% |
| Dec 31, 2025 | 17.44% |
| Sep 30, 2025 | 11.50% |
| Jun 30, 2025 | 26.06% |
| Mar 31, 2025 | 32.69% |
| Dec 31, 2024 | 23.79% |
| Sep 30, 2024 | 19.59% |
| Jun 30, 2024 | 12.89% |
| Mar 31, 2024 | 14.56% |
| Dec 31, 2023 | 17.80% |
| Sep 30, 2023 | 18.23% |
| Jun 30, 2023 | 15.91% |
| Mar 31, 2023 | 9.96% |
| Dec 31, 2022 | 9.19% |
| Sep 30, 2022 | 10.34% |
| Jun 30, 2022 | -3.37% |
| Mar 31, 2022 | 0.95% |
| Dec 31, 2021 | 10.17% |
| Sep 30, 2021 | 11.47% |